FDA Weighs Overseas Expansion Amid Scrutiny Of Foreign Oversight

FDA’s global policy shop is considering expanding its roster of overseas field offices in response to current drug manufacturing, supply chain and regulatory challenges that were exacerbated by the COVID-19 pandemic, an agency official told Asia-Pacific Economic Cooperation leaders last month, ahead of Republican criticisms that FDA is not doing enough to scrutinize foreign companies that provide pharmaceuticals to the United States. FDA is asking Congress for more authority to require that drug companies share data on active pharmaceutical ingredients...